PortalPublikationenTropomyosin receptor kinase C (TrkC) expression in medullobl...

Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response

Standard

Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. / Friedrich, Carsten; Shalaby, Tarek; Oehler, Christoph; Pruschy, Martin; Seifert, Burkhardt; Picard, Daniel; Remke, Marc; Warmuth-Metz, Monika; Kortmann, Rolf-Dieter; Rutkowski, Stefan; Grotzer, Michael A; von Bueren, André O.

in: CHILD NERV SYST, Jahrgang 33, Nr. 9, 09.2017, S. 1463-1471.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Friedrich, C, Shalaby, T, Oehler, C, Pruschy, M, Seifert, B, Picard, D, Remke, M, Warmuth-Metz, M, Kortmann, R-D, Rutkowski, S, Grotzer, MA & von Bueren, AO 2017, 'Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response', CHILD NERV SYST, Jg. 33, Nr. 9, S. 1463-1471. https://doi.org/10.1007/s00381-017-3506-y

APA

Friedrich, C., Shalaby, T., Oehler, C., Pruschy, M., Seifert, B., Picard, D., Remke, M., Warmuth-Metz, M., Kortmann, R-D., Rutkowski, S., Grotzer, M. A., & von Bueren, A. O. (2017). Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. CHILD NERV SYST, 33(9), 1463-1471. https://doi.org/10.1007/s00381-017-3506-y

Vancouver

Friedrich C, Shalaby T, Oehler C, Pruschy M, Seifert B, Picard D et al. Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. CHILD NERV SYST. 2017 Sep;33(9):1463-1471. https://doi.org/10.1007/s00381-017-3506-y

Bibtex

@article{a1d65992d2294853ba89b5836c41cb01,
title = "Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response",
abstract = "PURPOSE: High messenger RNA (mRNA) expression of the tropomyosin receptor kinase C gene (TrkC) has been associated with favorable survival in medulloblastoma patients. Untested is whether it plays a role through modulating the response to therapy or whether it might be a surrogate marker for a favorable molecular subgroup.METHODS: The medulloblastoma-derived cell line DAOY was stably transfected to overexpress TrkC (clone DAOY-TrkC) and compared to a control (clone DAOY-EV, empty vector transfected). Cell viability (MTS assay) was tested after irradiation or incubation with chemotherapeutic drugs. Neuroradiologic response to postoperative chemotherapy or craniospinal irradiation (CSI) of medulloblastoma patients aged 3-21 years with postoperative residual disease treated within the consecutive trials HIT'91/HIT2000 was compared to TrkC mRNA expression in their tumor samples. Five well-characterized independent expression-profiling studies covering together 686 medulloblastoma patients were analyzed for TrkC levels according to the molecular subgroups.RESULTS: Cell viability of DAOY-TrkC compared to DAOY-EV was not different after exposure to increasing doses of irradiation, cisplatin, etoposide, or vincristine. While TrkC mRNA expression tended to be higher in non-responders (n = 5/19) to postoperative CSI (p = 0.03, ratio 15.5, 95% CI 9-267), this was the case in responders (n = 23/43) to chemotherapy (p = 0.04, ratio 6.1, 95% CI 1.1-35), both analyzed with Mann-Whitney U test (not significant after Bonferroni adjustment). The highest TrkC mRNA levels were found in the SHH subgroup across all expression-profiling studies.CONCLUSIONS: High TrkC mRNA expression appears to be frequent in the SHH subgroup and seems not to have a major effect on therapy responsiveness in medulloblastoma patients.",
keywords = "Journal Article",
author = "Carsten Friedrich and Tarek Shalaby and Christoph Oehler and Martin Pruschy and Burkhardt Seifert and Daniel Picard and Marc Remke and Monika Warmuth-Metz and Rolf-Dieter Kortmann and Stefan Rutkowski and Grotzer, {Michael A} and {von Bueren}, {Andr{\'e} O}",
year = "2017",
month = sep,
doi = "10.1007/s00381-017-3506-y",
language = "English",
volume = "33",
pages = "1463--1471",
journal = "CHILD NERV SYST",
issn = "0256-7040",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response

AU - Friedrich, Carsten

AU - Shalaby, Tarek

AU - Oehler, Christoph

AU - Pruschy, Martin

AU - Seifert, Burkhardt

AU - Picard, Daniel

AU - Remke, Marc

AU - Warmuth-Metz, Monika

AU - Kortmann, Rolf-Dieter

AU - Rutkowski, Stefan

AU - Grotzer, Michael A

AU - von Bueren, André O

PY - 2017/9

Y1 - 2017/9

N2 - PURPOSE: High messenger RNA (mRNA) expression of the tropomyosin receptor kinase C gene (TrkC) has been associated with favorable survival in medulloblastoma patients. Untested is whether it plays a role through modulating the response to therapy or whether it might be a surrogate marker for a favorable molecular subgroup.METHODS: The medulloblastoma-derived cell line DAOY was stably transfected to overexpress TrkC (clone DAOY-TrkC) and compared to a control (clone DAOY-EV, empty vector transfected). Cell viability (MTS assay) was tested after irradiation or incubation with chemotherapeutic drugs. Neuroradiologic response to postoperative chemotherapy or craniospinal irradiation (CSI) of medulloblastoma patients aged 3-21 years with postoperative residual disease treated within the consecutive trials HIT'91/HIT2000 was compared to TrkC mRNA expression in their tumor samples. Five well-characterized independent expression-profiling studies covering together 686 medulloblastoma patients were analyzed for TrkC levels according to the molecular subgroups.RESULTS: Cell viability of DAOY-TrkC compared to DAOY-EV was not different after exposure to increasing doses of irradiation, cisplatin, etoposide, or vincristine. While TrkC mRNA expression tended to be higher in non-responders (n = 5/19) to postoperative CSI (p = 0.03, ratio 15.5, 95% CI 9-267), this was the case in responders (n = 23/43) to chemotherapy (p = 0.04, ratio 6.1, 95% CI 1.1-35), both analyzed with Mann-Whitney U test (not significant after Bonferroni adjustment). The highest TrkC mRNA levels were found in the SHH subgroup across all expression-profiling studies.CONCLUSIONS: High TrkC mRNA expression appears to be frequent in the SHH subgroup and seems not to have a major effect on therapy responsiveness in medulloblastoma patients.

AB - PURPOSE: High messenger RNA (mRNA) expression of the tropomyosin receptor kinase C gene (TrkC) has been associated with favorable survival in medulloblastoma patients. Untested is whether it plays a role through modulating the response to therapy or whether it might be a surrogate marker for a favorable molecular subgroup.METHODS: The medulloblastoma-derived cell line DAOY was stably transfected to overexpress TrkC (clone DAOY-TrkC) and compared to a control (clone DAOY-EV, empty vector transfected). Cell viability (MTS assay) was tested after irradiation or incubation with chemotherapeutic drugs. Neuroradiologic response to postoperative chemotherapy or craniospinal irradiation (CSI) of medulloblastoma patients aged 3-21 years with postoperative residual disease treated within the consecutive trials HIT'91/HIT2000 was compared to TrkC mRNA expression in their tumor samples. Five well-characterized independent expression-profiling studies covering together 686 medulloblastoma patients were analyzed for TrkC levels according to the molecular subgroups.RESULTS: Cell viability of DAOY-TrkC compared to DAOY-EV was not different after exposure to increasing doses of irradiation, cisplatin, etoposide, or vincristine. While TrkC mRNA expression tended to be higher in non-responders (n = 5/19) to postoperative CSI (p = 0.03, ratio 15.5, 95% CI 9-267), this was the case in responders (n = 23/43) to chemotherapy (p = 0.04, ratio 6.1, 95% CI 1.1-35), both analyzed with Mann-Whitney U test (not significant after Bonferroni adjustment). The highest TrkC mRNA levels were found in the SHH subgroup across all expression-profiling studies.CONCLUSIONS: High TrkC mRNA expression appears to be frequent in the SHH subgroup and seems not to have a major effect on therapy responsiveness in medulloblastoma patients.

KW - Journal Article

U2 - 10.1007/s00381-017-3506-y

DO - 10.1007/s00381-017-3506-y

M3 - SCORING: Journal article

C2 - 28695340

VL - 33

SP - 1463

EP - 1471

JO - CHILD NERV SYST

JF - CHILD NERV SYST

SN - 0256-7040

IS - 9

ER -